Log In
BCIQ
Print this Print this
 

Diamyd

Also known as: Diabetes vaccine (GAD65 antigen based therapy)

  Manage Alerts
Collapse Summary General Information
Company Diamyd Medical AB
DescriptionRecombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine
Molecular Target Glutamate decarboxylase 2 (GAD2) (GAD65)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsPreserve insulin production in patients with recent-onset Type I diabetes; Prevent insulin-dependent diabetes; Prevent latent autoimmune diabetes in adults (LADA); Prevent or treat Type I diabetes; Prevent Type I diabetes; Treat Type I diabetes; Treat Type I diabetes with residual beta cell function; Treat Type II diabetes
Regulatory Designation U.S. - Orphan Drug (Treat Type I diabetes with residual beta cell function)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$625.0M

$45.0M

$580.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/28/2010

$625.0M

$45.0M

$580.0M

Get a free BioCentury trial today